Pharming Group (CHIX:PHARMA) Other Current Payables: €0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:PHARMA Pharming Group CHIX:PHARMA
74 GF Score
Price €1.26
GF Value €1.40
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Pharming Group Other Current Payables?

Pharming Group CHIX:PHARMA 74 Other Current Payables is €0.0 Mil as of Mar. 2026. GuruFocus rates CHIX:PHARMA with a GF Score™ of 74/100 and a GF Value™ of €1.40 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Pharming Group's Other Current Payables for the quarter that ended in Mar. 2026 was €0.0 Mil.

Pharming Group's quarterly Other Current Payables increased from Sep. 2025 (€0.0 Mil) to Dec. 2025 (€0.0 Mil) but then declined from Dec. 2025 (€0.0 Mil) to Mar. 2026 (€0.0 Mil).

Pharming Group's annual Other Current Payables increased from Dec. 2023 (€0.0 Mil) to Dec. 2024 (€0.0 Mil) but then declined from Dec. 2024 (€0.0 Mil) to Dec. 2025 (€0.0 Mil).

Pharming Group Other Current Payables Related Terms

Pharming Group Other Current Payables Historical Data

* Premium members only.

The historical data trend for Pharming Group's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharming Group Other Current Payables Chart

Pharming Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.00 0.00 0.00 0.00

Pharming Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CHIX:PHARMA
74GF Score
Pharming Group CHIX:PHARMA
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharming Group Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of €0.0 Mil mean?
Pharming Group (CHIX:PHARMA) has a Other Current Payables of €0.0 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Pharming Group and its competitors.
Is Pharming Group's Other Current Payables too high?
Pharming Group's current Other Current Payables is €0.0 Mil. Overall, Pharming Group has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharming Group's Other Current Payables compare to VRTX and REGN?
Pharming Group's Other Current Payables of €0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Pharming Group and its competitors. Pharming Group's current Other Current Payables is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharming Group stock overvalued right now?
Based on GuruFocus' analysis, Pharming Group (CHIX:PHARMA) is currently considered Modestly Undervalued. The stock's GF Value™ is €1.40, compared to a current price of €1.26 — trading 9.7% below its estimated fair value. The current Other Current Payables is €0.0 Mil. Pharming Group's overall GF Score™ is 74/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Pharming Group (CHIX:PHARMA), the current Other Current Payables is €0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharming Group (CHIX:PHARMA) Overvalued in 2026?

Based on GuruFocus' analysis, Pharming Group stock appears to be undervalued. The current stock price of €1.26 is trading 9.7% below its estimated GF Value™ of €1.40. GuruFocus considers Pharming Group to be Modestly Undervalued.

Key valuation signals for CHIX:PHARMA:

  • Other Current Payables: €0.0 Mil
  • GF Value™: €1.40 vs. price of €1.26 (9.7% below fair value)
  • GF Score™: 74/100 with 1 warning sign

No single metric tells the full story. See the CHIX:PHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharming Group Business Description

Address Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
74GF Score

Get the complete analysis for CHIX:PHARMA

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.26
Price
€1.40
GF Value